We have initiated and developed over the last decade a translational methodology, convergent functional genomics (CFG), that integrates in a Bayesian fashion multiple lines of evidence from human and animal model studies (Figure 1). This approach has been applied, among others, to the study of bipolar disorder (Le-Niculescu et al, 2009b; Niculescu et al, 2000; Ogden et al, 2004) and schizophrenia (Le-Niculescu et al, 2007), as well as to the identification of blood biomarkers (Le-Niculescu et al, 2009a). Human data increase the relevance to the disorder (specificity), whereas animal model data increase the ability to identify the signal (sensitivity). Combined, we have an approach that increases our ability to distinguish signal from noise even with limited size cohorts and datasets. The CFG approach also increases the likelihood that the findings will prove reproducible and have predictive power in independent cohorts, which is a key litmus test for genetic and biomarker studies.
The emerging picture from psychiatric genetics, in which our CFG approach has had a decade's head start, is that gene-level, followed by pathway-level and mechanisms-level, analyses appear to be the way to go, as opposed to focusing exclusively on identifying genetic polymorphisms. The latter method of analysis by itself is proving unwieldy because of the sheer number of common and rare variants involved (complexity) and the diversity (heterogeneity) in the population. A combined approach such as CFG, which is focused on gene-level integration, can harness the present and future body of work in the field to yield a successful outcome, truly reflecting, in essence, a field-wide collaboration (Le-Niculescu et al, 2009b).
We have built in our laboratory a large and evolving CFG-curated database, integrating our own datasets and published data in the field of psychiatric genetics and genomics, comprising at this point over 7000 genes. Using this database, there is an emerging appreciation at genetic, neurobiological, and phenotypic levels of the complexity, heterogeneity, overlap, and interdependence of major psychiatric disorders. For example, in our earlier work we have provided evidence of a significant molecular overlap between bipolar disorder and schizophrenia (Le-Niculescu et al, 2007), which has been confirmed by more recent independent studies. Based on our work and that of others in the field, we believe that the cumulative combinatorics of common (normal) genetic variants may underlie the vulnerability or resilience to disease, in lieu of or in addition to rare (abnormal) mutations. We have proposed a combinatorial modular Lego® game-like model for psychiatric disorders (Le-Niculescu et al, 2007; Niculescu et al, 2006).
It is likely that panels of markers (SNPs, biomarkers) rather than single markers will emerge as useful profiling tools for personalized/precision medicine approaches. We anticipate that using CFG to choose and prioritize markers for panels will ensure (1) generalizability across independent cohorts rather than just a good fit to the cohort from which the markers were derived, and (2) a sufficiently strong signal to differentiate across the razor-thin margin that may exist between normalcy and illness.
Diagnosis will remain a complex undertaking, in which the integration of clinical data, biomarker testing, genetic testing, imaging, and other modalities will be factored in as our knowledge evolves.
References
Le-Niculescu H, Balaraman Y, Patel S, Tan J, Sidhu K, Jerome RE et al (2007). Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am J Med Genet B Neuropsychiatr Genet 144B: 129–158.
Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ et al (2009a). Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry 14: 156–174.
Le-Niculescu H, Patel SD, Bhat M, Kuczenski R, Faraone SV, Tsuang MT et al (2009b). Convergent functional genomics of genome-wide association data for bipolar disorder: comprehensive identification of candidate genes, pathways and mechanisms. Am J Med Genet B Neuropsychiatr Genet 150B: 155–181.
Niculescu A, Segal D, Kuczenski R, Barrett T, Hauger R, Kelsoe J (2000). Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach. Physiol Genomics 4: 83–91.
Niculescu AB, Lulow LL, Ogden CA, Le-Niculescu H, Salomon DR, Schork NJ et al (2006). PhenoChipping of psychotic disorders: a novel approach for deconstructing and quantitating psychiatric phenotypes. Am J Med Genet B Neuropsychiatr Genet 141: 653–662.
Ogden CA, Rich ME, Schork NJ, Paulus MP, Geyer MA, Lohr JB et al (2004). Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. Mol Psychiatry 9: 1007–1029.
Author information
Authors and Affiliations
Corresponding author
Additional information
DISCLOSURE
Dr Niculescu has received research support from NIH, NARSAD, and Eli Lilly and Co., and also received honoraria as a speaker from Pfizer and Janssen. He is a scientific co-founder of Mindscape Diagnostics. Dr Le-Niculescu has received research support from the NIH, and Eli Lilly and Co.
Rights and permissions
About this article
Cite this article
Niculescu, A., Le-Niculescu, H. Convergent Functional Genomics: what we have learned and can learn about genes, pathways, and mechanisms. Neuropsychopharmacol 35, 355–356 (2010). https://doi.org/10.1038/npp.2009.107
Published:
Issue Date:
DOI: https://doi.org/10.1038/npp.2009.107
This article is cited by
-
Blood biomarker-based classification study for neurodegenerative diseases
Scientific Reports (2023)
-
Functional Genomics of Epileptogenesis in Animal Models and Humans
Cellular and Molecular Neurobiology (2021)
-
Further confirmation of netrin 1 receptor (DCC) as a depression risk gene via integrations of multi-omics data
Translational Psychiatry (2020)
-
Prediction of Alzheimer’s disease using blood gene expression data
Scientific Reports (2020)
-
Integrative analyses of major histocompatibility complex loci in the genome-wide association studies of major depressive disorder
Neuropsychopharmacology (2019)